Effect of gemtuzumab ozogamicin on acute myeloid leukaemia blast cells in vitro, as a single agent and combined with other cytotoxic agents

被引:12
|
作者
Morris, K. L. [1 ]
Adams, J. A. [1 ]
Yin, J. A. Liu [1 ]
机构
[1] Univ Manchester, Manchester Royal Infirm, Dept Clin Haematol, Manchester M13 9WL, Lancs, England
关键词
gemtuzumab ozogamicin (mylotarg); acute myeloid leukaemia; apoptosis; co-incubation; multi drug resistance;
D O I
10.1111/j.1365-2141.2006.06326.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effect of gemtuzumab ozogamicin (GO) alone, or combined with low-dose cytarabine or etoposide, on the proliferation of acute myeloid leukaemia blast cells in vitro was investigated. GO alone induced a dose-dependent inhibition of proliferation although an increase in apoptosis was only seen in a minority of patients. A correlation was found between PgP function and GO sensitivity but not between CD33 or PgP expression and GO. Combinations of GO with varying concentrations of cytarabine or etoposide were additive in inhibiting proliferation, reducing cell viability and increasing apoptosis.
引用
收藏
页码:509 / 512
页数:4
相关论文
共 50 条
  • [31] The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs
    Paulus, Aneel
    Masood, Aisha
    Miller, Kena C.
    Khan, A. N. M. Nazmul H.
    Akhtar, Drusilla
    Advani, Pooja
    Foran, James
    Rivera, Candido
    Roy, Vivek
    Colon-Otero, Gerardo
    Chitta, Kasyapa
    Chanan-Khan, Asher
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (01) : 78 - 88
  • [32] Significance of Blast CD33 Expression for Effect of Gemtuzumab Ozogamicin at Different Doses in Adult Acute Myeloid Leukemia: Results from the UK NCRI AML16/17 Trials
    Naeem, Khan
    Hills, Robert K.
    Virgo, Paul
    Couzens, Stephen
    Clark, Nithiya
    Gilkes, Amanda
    Grech, Angela
    Richardson, Peter
    Knapper, Steven
    Grimwade, David
    Russell, Nigel H.
    Burnett, Alan K.
    Freeman, Sylvie
    BLOOD, 2015, 126 (23)
  • [33] Epigenetic therapy with chidamide alone or combined with 5-azacitidine exerts antitumour effects on acute myeloid leukaemia cells in vitro
    Li, Zheng
    Zhang, Jian
    Zhou, Min
    Li, Jin-Li
    Qiu, Qiao-Cheng
    Fu, Jian-Hong
    Xue, Sheng-Li
    Qiu, Hui-Ying
    ONCOLOGY REPORTS, 2022, 47 (04)
  • [34] In vivo priming with rhG-CSF increases the expression of CD33 in acute myeloid leukemia blast cells and possibly enhances the cytotoxic effect of Gemtuzumab-Ozamicin: Results of a pilot study.
    Leone, G
    Rutella, S
    Scardocci, A
    Voso, MT
    Pagano, L
    BLOOD, 2003, 102 (11) : 256B - 256B
  • [35] Combined Activity of the Redox-Modulating Compound Setanaxib (GKT137831) with Cytotoxic Agents in the Killing of Acute Myeloid Leukemia Cells
    Demircan, Muhammed Burak
    Mgbecheta, Peter C.
    Kresinsky, Anne
    Schnoeder, Tina M.
    Schroeder, Katrin
    Heidel, Florian H.
    Boehmer, Frank D.
    ANTIOXIDANTS, 2022, 11 (03)
  • [36] Gemtuzumab ozogamicin (Mylotarg®) as a single agent to evaluate safety and determine maximum tolerated dose (MTD) in post hemopoeitic stem cell transplant patients with relapsed, CD33+ acute myeloid leukemia (AML).
    Sievers, EL
    Spielberger, R
    Brunvand, MW
    Feingold, J
    Culleton, V
    Armstrong, P
    Resnick, GD
    Roth, DC
    BLOOD, 2002, 100 (11) : 336A - 336A
  • [37] Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study (vol 379, pg 1508, 2012)
    Castaigne, S.
    Pautas, C.
    Terre, C.
    LANCET, 2018, 391 (10123): : 838 - 838
  • [38] In vitro activity of the FLT3-inhibitor SU5614 and standard cytotoxic agents in tumour cells from patients with wild type and mutated FLT3 acute myeloid leukaemia
    Åleskog, A
    Höglund, M
    Pettersson, J
    Hermansson, M
    Larsson, R
    Lindhagen, E
    LEUKEMIA RESEARCH, 2005, 29 (09) : 1079 - 1081
  • [39] Gemtuzumab ozogamicin, fludarabine, ara-C and cyclosporineA (MFAC) regimen as induction therapy in relapsed or refractory CD33+acute myeloid leukaemia prior to allogeneic haematopoetic stem cell transplantation: a single-centre experience
    von Bonin, M.
    Oelschlaegel, U.
    Mohr, B.
    Platzbecker, U.
    Thiede, C.
    Bornhaeuser, M.
    Ehninger, G.
    Illmer, T.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S95 - S96
  • [40] Effect of Small Interfering RNA Targeting Wild-type FLT3 in Acute Myeloid Leukaemia Cells In Vitro and In Vivo
    Wang, C-M
    Sheng, G-Y
    Lu, J.
    Xie, L.
    Bai, S-T
    Xu, X-J
    Liu, Y-F
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2011, 39 (05) : 1661 - 1674